0001209191-17-028628.txt : 20170428
0001209191-17-028628.hdr.sgml : 20170428
20170428135607
ACCESSION NUMBER: 0001209191-17-028628
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170428
FILED AS OF DATE: 20170428
DATE AS OF CHANGE: 20170428
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Zeltiq Aesthetics Inc
CENTRAL INDEX KEY: 0001415336
STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
IRS NUMBER: 270119051
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4410 ROSEWOOD DRIVE
CITY: Pleasanton
STATE: CA
ZIP: 94588
BUSINESS PHONE: (925) 474-2500
MAIL ADDRESS:
STREET 1: 4410 ROSEWOOD DRIVE
CITY: Pleasanton
STATE: CA
ZIP: 94588
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Zavodnick Todd Erik
CENTRAL INDEX KEY: 0001660467
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35318
FILM NUMBER: 17794050
MAIL ADDRESS:
STREET 1: C/O ZELTIQ AESTHETICS, INC.
STREET 2: 4698 WILLOW ROAD, SUITE 100
CITY: PLEASANTON
STATE: CA
ZIP: 94588
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-04-28
1
0001415336
Zeltiq Aesthetics Inc
ZLTQ
0001660467
Zavodnick Todd Erik
C/O ZELTIQ AESTHETICS, INC.
4410 ROSEWOOD DRIVE
PLEASANTON
CA
94588
0
1
0
0
President, International
Common Stock
2017-04-28
4
D
0
99971
D
0
D
Stock Option (right to buy)
40.89
2017-04-28
4
D
0
16674
0.00
D
2027-01-17
Common Stock
16674
0
D
Disposed of pursuant to the Agreement and Plan of Merger, dated as of February 13, 2017, by and among Allergan Holdco US, Inc. a wholly owned subsidiary of Allergan plc ("Allergan"), Blizzard Merger Sub, Inc. ("Merger Sub"), and the Issuer (the "Merger Agreement"), as approved by the board of directors of the Issuer (the "Board"), whereby Merger Sub merged with and into the Issuer, with the Issuer continuing on as the surviving corporation (the "Merger"). In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all 99,971 shares were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes.
In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all shares subject to this option were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes.
/s/ Sergio Garcia, Attorney-in-Fact
2017-04-28